Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program
Shots:
- Gilead entered into a strategic collaboration with Glympse Bio to utilize Glympse’s technology- Glympse Inside in its NASH program to diagnose the stage of NASH as well as early detection of treatment response
- The focus of the collaboration is to meet highly unmet medical needs and to improve the lives of patients by transforming the disease detection and measuring treatment response
- Glympse Inside is a pan-disease product engine focusing on transforming disease monitoring and treatment response by integrating synthetic biomarkers with machine learning and AI
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com